Cargando…

Performance of a Predictive Model for Long-Term Hemoglobin Response to Darbepoetin and Iron Administration in a Large Cohort of Hemodialysis Patients

Anemia management, based on erythropoiesis stimulating agents (ESA) and iron supplementation, has become an increasingly challenging problem in hemodialysis patients. Maintaining hemodialysis patients within narrow hemoglobin targets, preventing cycling outside target, and reducing ESA dosing to pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Barbieri, Carlo, Bolzoni, Elena, Mari, Flavio, Cattinelli, Isabella, Bellocchio, Francesco, Martin, José D., Amato, Claudia, Stopper, Andrea, Gatti, Emanuele, Macdougall, Iain C., Stuard, Stefano, Canaud, Bernard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4777424/ https://www.ncbi.nlm.nih.gov/pubmed/26939055 http://dx.doi.org/10.1371/journal.pone.0148938

Ejemplares similares

Optimal convection volume for improving patient outcomes in an international incident dialysis cohort treated with online hemodiafiltration
por: Canaud, Bernard, et al.
Publicado: (2015)

Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability
por: Arrieta, Javier, et al.
Publicado: (2014)

Reticulocyte dynamic and hemoglobin variability in hemodialysis patients treated with Darbepoetin alfa and C.E.R.A.: a randomized controlled trial
por: Forni, Valentina, et al.
Publicado: (2013)

A pharmacist‐managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial
por: van den Oever, Francisca Johanna, et al.
Publicado: (2020)

Greater fluid overload and lower interdialytic weight gain are independently associated with mortality in a large international hemodialysis population
por: Hecking, Manfred, et al.
Publicado: (2018)

Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
por: Akizawa, Tadao, et al.
Publicado: (2020)

Maintenance treatment of renal anaemia in haemodialysis patients with methoxy polyethylene glycol-epoetin beta versus darbepoetin alfa administered monthly: a randomized comparative trial
por: Carrera, Fernando, et al.
Publicado: (2010)

Iron status and erythropoiesis response to darbepoetin alfa in dogs with chronic kidney disease
por: BHAMARASUTA, Chayanont, et al.
Publicado: (2021)

Ferric pyrophosphate citrate (Triferic™) administration via the dialysate maintains hemoglobin and iron balance in chronic hemodialysis patients
por: Fishbane, Steven N., et al.
Publicado: (2015)

Effect of occasional epoetin use in combination with a stable darbepoetin dosage on anemia management in hemodialysis patients
por: Shimamatsu, Kazumasa
Publicado: (2014)

Costs Associated With Intravenous Darbepoetin Versus Epoetin Therapy in Hemodialysis Patients: A Randomized Controlled Trial
por: Woodland, Andrea L., et al.
Publicado: (2017)

Choices in hemodialysis therapies: variants, personalized therapy and application of evidence-based medicine
por: Canaud, Bernard, et al.
Publicado: (2021)

Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients
por: de Francisco, Angel L.M., et al.
Publicado: (2017)

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe
por: Deger, Melike, et al.
Publicado: (2012)

Dose Conversion Ratio in Hemodialysis Patients Switched from Darbepoetin Alfa to PEG-Epoetin Beta: AFFIRM Study
por: Choi, Peter, et al.
Publicado: (2013)

The Cost-Effectiveness of Using Epoetin-Beta Versus Darbepoetin-Alfa for the Treatment of Anemia Among Chronic Hemodialysis Patients
por: AlKharboush, Hanan, et al.
Publicado: (2020)

Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial
por: Macdougall, Iain C., et al.
Publicado: (2019)

Serum Uric Acid and Mortality Risk Among Hemodialysis Patients
por: Zawada, Adam M., et al.
Publicado: (2020)

Oral sucrosomial iron versus intravenous iron in anemic cancer patients without iron deficiency receiving darbepoetin alfa: a pilot study
por: Mafodda, Antonino, et al.
Publicado: (2017)

Clinical outcomes of hemodialysis patients in a public-private partnership care framework in Italy: a retrospective cohort study
por: Pedrini, L. A., et al.
Publicado: (2019)

Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy‐induced anemia
por: Boccia, Ralph V., et al.
Publicado: (2016)

Effects of the route of erythropoietin administration on hemoglobin variability and cardiovascular events in hemodialysis patients
por: Kim, Do Hyoung, et al.
Publicado: (2021)

Darbepoetin alpha in the treatment of cancer chemotherapy-induced anemia
por: Grossi, Alberto, et al.
Publicado: (2007)

Extended dosing of darbepoetin alfa in peritoneal dialysis patients
por: Feriani, Mariano, et al.
Publicado: (2011)

From electronic health records to clinical management systems: how the digital transformation can support healthcare services
por: Barbieri, Carlo, et al.
Publicado: (2023)

Modifiable Risk Factors Are Important Predictors of COVID-19-Related Mortality in Patients on Hemodialysis
por: Kooman, Jeroen Peter, et al.
Publicado: (2022)

Beyond the cardiorenal anaemia syndrome: recognizing the role of iron deficiency
por: Macdougall, Iain C., et al.
Publicado: (2012)

A Safe and Easy Introduction of Darbepoetin-Alpha in Patients Receiving Maintenance Hemodialysis and Epoetin Monotherapy: A “Half-and-Half” Combination Therapy()
por: Shimamatsu, Kazumasa, et al.
Publicado: (2013)

Effectiveness of COVID-19 vaccines in a large European hemodialysis cohort
por: Bernardo, Ana Paula, et al.
Publicado: (2022)

Flexible dosing with Darbepoetin alfa for the treatment of chemotherapy-induced anemia
por: Wauters, Isabelle, et al.
Publicado: (2006)

Acute onset anterior uveitis after darbepoetin alfa infusion
por: Li, Jonathan, et al.
Publicado: (2015)

Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study
por: Nangaku, Masaomi, et al.
Publicado: (2021)

Hypoxia-inducible factor prolyl hydroxylase domain inhibitor may maintain hemoglobin synthesis at lower serum ferritin and transferrin saturation levels than darbepoetin alfa
por: Ogawa, Chie, et al.
Publicado: (2021)

Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial
por: Maruyama, Shoichi, et al.
Publicado: (2023)

Iron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?
por: McDonagh, Theresa, et al.
Publicado: (2015)

Sodium, volume and pressure control in haemodialysis patients for improved cardiovascular outcomes
por: Pinter, Jule, et al.
Publicado: (2020)

Special issue: iron therapy in patients with chronic kidney disease
por: Macdougall, Iain C
Publicado: (2017)

Preservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study
por: Donck, Jan, et al.
Publicado: (2014)

Darbepoetin, effective treatment of anaemia in paediatric patients with chronic renal failure
por: André, Jean-Luc, et al.
Publicado: (2007)

Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin
por: Sepah, Yasir J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ufeuikadqjs91ml4crsha19uve